# Sequential Belimumab and T-cell Based Therapy in SLE

> **NCT04447053** · PHASE4 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 80 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab Injection [Benlysta]

## Key facts

- **NCT ID:** NCT04447053
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-08
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447053, "Sequential Belimumab and T-cell Based Therapy in SLE". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04447053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*